Infliximab
Infliximab or Remicade is a chimeric monoclonal antibody that reduces production of TNF-alpha (tumour necrosis factor alpha) which has been shown to be part of the autoimmune component in Crohn's Disease and Rehoumatoid Arthritis. It is made up of part-human part mouse protein, and is administered by infusion (usually on an outpatient basis). Before infliximab is administered a test for tuberculosis must be performed, as potential adverse side effects affecting breathing can be severe in patients with untreated tuberculosis. Potential side effects include skin rash, fever, tiredness and difficulty breathing.